Ocular Therapeutix™ to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
09 Agosto 2023 - 9:00AM
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that Antony Mattessich,
President and Chief Executive Officer of Ocular Therapeutix, will
participate in a panel at the H.C. Wainwright 3rd Annual
Ophthalmology Virtual Conference on Wednesday, August 16, 2023 at
11:00 AM EDT.
In addition to the panel, the management team will host investor
meetings at the conference. Investors participating in the
conference who are interested in meeting with Ocular Therapeutix
management should contact their H.C. Wainwright representative.
A live webcast of the panel can be accessed by visiting the
Investors section of the Company’s website at
investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company
focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary bioresorbable hydrogel-based formulation
technology. Ocular Therapeutix’s first commercial drug product,
DEXTENZA®, is an FDA-approved corticosteroid for the treatment of
ocular inflammation and pain following ophthalmic surgery and
ocular itching associated with allergic conjunctivitis. Ocular
Therapeutix’s earlier stage development assets include: OTX-TKI
(axitinib intravitreal implant), currently in Phase 1 clinical
trials for the treatment of wet AMD and diabetic retinopathy;
OTX-TIC (travoprost intracameral implant), currently in a Phase 2
clinical trial for the treatment of primary open-angle glaucoma or
ocular hypertension; and OTX-CSI (cyclosporine intracanalicular
insert) for the chronic treatment of dry eye disease and OTX-DED
(dexamethasone intracanalicular insert) for the short-term
treatment of the signs and symptoms of dry eye disease, both of
which have completed Phase 2 clinical trials.
InvestorsOcular TherapeutixDonald NotmanChief
Financial Officerdnotman@ocutx.com
or
ICR Westwicke Chris BrinzeyManaging
Directorchris.brinzey@westwicke.com
Ocular Therapeutix (NASDAQ:OCUL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Ocular Therapeutix (NASDAQ:OCUL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024